期刊文献+

健康人外周血树突状细胞的体外诱导及其功能分析 被引量:2

Functional analysis of dendritic cells from peripheral blood of the healthy people induced in vitro
原文传递
导出
摘要 目的分析以健康人AB血清与rhCD40L体外诱导健康人外周血树突状细胞(Dc)的功能。方法对健康人外周血单个核细胞进行体外培养,在以健康人AB血清为基础的培养体系中加入粒细胞巨噬细胞集落刺激因子(GM-CSF)、重组人白细胞介素(rhIL)-4、rhCDnoL等细胞因子,诱导单个核细胞分化形成DC,采用倒置显微镜及瑞特-吉姆萨染色观察,流式细胞术行DC表型鉴定,四甲基偶氮唑蓝比色(MTT)法进行混合淋巴细胞反应(MLR),检测其抗原刺激能力,酶联免疫吸附(ELISA)法检测DC培养上清IL-12的分泌。结果培养7d后的细胞具有典型的DC形态,并上调表达DC特征性表面分子CD83及共刺激分子CD40、CD80、CD86,第0、1、3、5、7天,5个时间点间CD83、CD40、CD80、CD86、CD14表达差异有统计学意义(F值分别为50.253、243.769、248.181、191.267、226.339,均P〈0.05)。培养后的DC可较强地刺激同种自体淋巴细胞增殖,GM-CSF加rhIL-4、rhCD40L组较GM—CSF加rhIL-4组刺激反应能力强。培养的DC自培养第5天始即有IL-12分泌,未加CD40L组IL-12p40分泌量为(42.92±1.54)Pg/ml,加CD40L组为(136.18±5.27)Pg/ml;培养第7天,IL-12p40分泌明显增多,两组分别为(60.09±2.27)pg/ml及(322.30±30.60)Pg/ml,差异有统计学意义(t=-44.941、-22.611,均P〈0.05)。结论健康人外周血单个核细胞可在以健康人AB血清与rhCD40L为主的培养体系中诱导成DC。 Objective To establish a method to induce dendritic cells (DC) from peripheral blood mononuclear cells of healthy people in normal human AB serum in vitro and to identify the phenotype and the function of DC. Methods Peripheral blood mononuclear cells (PBMNC) of healthy people were cultured in RPMI 1640 media including human AB serum, GM-CSF, rhIL-4, and/no rhCD40L for 7 days to generate DC, which were identified by morphological features, surface antigen expression and the ability to stimulate T cells. Results After cultured and induced, DC displayed typical morphology with elongated dendritic process viewed by inverse light microscope as well as Wright-Gimsa stain. Mature DC express CD83 and the costimulatory molecules CD40, CD80 and CD86 to effectively activate T cells. In the five time points of 0 day, 1st day, 3rd day, 5th day and 7th day, the expression of CD83, CD40, CD80, CD86 and CD14 were significantly different (F = 50.253, 243.769, 248.181, 191.267 and 226.339, respectively, P 〈 0.05). The ability to stimulate T ceils in GM-CSF, rhIL-4, and rhCD40L group was also stronger than that in GM-CSF and rhlL-4 group. DC started to secrete IL-12 from 5th day, the values were (42.92±1.54) pg/ml and (136.18±5.27) pg/ml in group of plus CD40L and of non plus CD40L, respectively. The secretion of the two groups of IL-12 were (60.09±2.27) pg/ml and (322.30±30.60) pg/ml (t = -44.941, -22.611, bath P 〈 0.05). There are significant differences between the two groups. Conclusion DCs can be cultured from the peripheral blood of healthy people in normal human AB and rhCD40L serum.
出处 《白血病.淋巴瘤》 CAS 2011年第8期482-485,共4页 Journal of Leukemia & Lymphoma
关键词 树突状细胞 髓性 白血病 急性 正常人AB血清 rhCD40L Dendritic cells Myelogenous, leukemia, acute Normal human AB serum
  • 相关文献

参考文献21

  • 1van den Ancker W,Westers TM,Ossenkoppele GJ,et al.Back to basics:in search of the optimal dendritic cell for vaccination in AML.Leuk Res,2008,32:1641-1643.
  • 2Boyer PJ,Bougras G,Ebstein F,et al.Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment:application to active immunotherapy.Exp Hematol,2008,36:329-339.
  • 3Estey E,D(o)hner H.Acute myeloid leukaemia.Lancet,2006,368:1894-1907.
  • 4Burnett AK,Wheatley K,Goldstone AH,et al.The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse.:results of the UK MRC AML 10 trial.Br J Haematol,2002,118:385-400.
  • 5Duncan C,Roddie H.Dendritic cell vaccines in acute leukaemia.Best Pract Bes Clin Haematol,2008,21:521-541.
  • 6Zhang WG,Liu SH,Cao XM,et al.A phase-Ⅰ clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2,GM-CSF,and IL-6.Leuk Res,2005,29:3-9.
  • 7Blair A,Goulden NJ,Libri NA,et al.Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.Blood Rev,2005,19:289-300.
  • 8Westers TM,Ossenkoppele GJ,van de Loosdrecht AA.Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.Biomed Pharmacother,2007,61:306-314.
  • 9Houtenbos I,Westers TM,Ossenkoppele GJ,et al.Leukemia-derived dendritic cells:towards clinical vaccination protocols in acute myeloid leukemia.Haematologica,2006,91:348-355.
  • 10Allgeier T,Garhammer S,N(o)ssner E,et al.Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia.Cancer Lett,2007,245:275-283.

同被引文献15

  • 1曾东风,孔佩艳,陈幸华,彭贤贵,魏立,常诚,刘林,刘红,王庆余.SDF-1及其受体CXCR4在急性白血病与淋巴瘤表达的初步研究[J].中国实验血液学杂志,2005,13(2):274-277. 被引量:29
  • 2Voermans C,van Heese WP,de Jong I,et al.Migratory behavior of leukemic cells from acute myeloid leukemia patients(J).Eukemia,2002;16(4):649-50.
  • 3Guang LG,Boskey AL,Zhu W.Regulatory role of stromal cell-derived factor-1 in bone morphogenetic protein-2-induced chondrogenic differentiation in vitro(J).Int J Biochem Cell Biol,2012;44(11):1825-33.
  • 4Kalinkovich A,Tavor S,Avigdor A.Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells(J).Cancer Res,2006;66(2):11013-20.
  • 5Tavor S,Petit I.Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia(J)?Semin Cancer Biol,2010;20(3):178-85.
  • 6Parameswaran R,Yu M,Lim M,et al.Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist(J).Leukemia,2011;25(8):1314-23.
  • 7Spiegel A,Kollet O,Peled A,et al.Unique SDF-l-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling(J).Blood,2004;103(8):2900-7.
  • 8Guang LG, Boskey AL, Zhu W. Regulatory role of stromal cell-derived actor-i in bone morphogenetic protein-2-in- duced chondrogenic differentiation in vitro [ J ]. Int J Bio- chem Cell Biol,2012,44( 11 ):1825-1833.
  • 9Scorsone K, Blaney S, Bomgaars L, et al. Matrix metallopro- teinases and tissue inhibitor of metalloproteinase-1 in the ce- rebrospinal fluid of children with central nervous system ma- lignancies [ J]. Cancer Res, 2004,64 ( 7 ) :419.
  • 10Tavor S, Petit I. Can inhibition of the SDF-1 /CXCR4 axis e- radicate acute leukemia [ J]. Semin Cancer Biol, 2010,20 (3) :178-185.

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部